Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 179, Issue 11, 2009, Pages 1055-1060

  Holland, David P ^a   Sanders, Gillian D ^a   Hamilton, Carol D ^a,b   Stout, Jason E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Antitubercular agents; Cost benefit analysis; HIV infections

Indexed keywords

ISONIAZID; RIFAMPICIN; RIFAPENTINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG COST; DRUG EFFICACY; DRUG SELF ADMINISTRATION; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SHORT COURSE THERAPY; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; ISONIAZID; MARKOV CHAINS; RIFAMPIN; TUBERCULOSIS;

EID: 66249087657     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200901-0153OC     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54:1-47.
2. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
3. Comstock GW. Frost revisited: the modern epidemiology of tuberculosis. Am J Epidemiol 1975;101:363-382.
4. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-2067.
5. International Union against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
6. LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003;168:443-447. (Pubitemid 37046873)
7. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-449. (Pubitemid 39214621)
8. Jasmer RM, Snyder DC, Chin DP, Hopewell PC, Cuthbert SS, Antonio PE, Daley CL. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis. Am J Respir Crit Care Med 2000;162:1648-1652.
9. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006;130:1712-1717. (Pubitemid 46033423)
10. Weiner M, Bock N, Peloquin CA, Burman WJ, Kahn A, Vernon A, Zhao Z, Weis S, Sterling TR, Hayden K. et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med 2004;169:1191-1197. (Pubitemid 38680395)
11. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburg CR, Horton J, Kahn A. et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 2002;360:528-534.
12. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD. et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
13. Schechter M, Zajdenverg R, Falco G, Barnes GL, Faulhaber JC, Coberly JS, Moore RD, Chaisson RE. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med 2006;173:922-926.
14. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258. (Pubitemid 26337709)
15. Gross Domestic Product Deflator Inflation Calculator. Budget of the United States Government, Fiscal year 2005, historical tables [Internet]. (accessed October 16, 2008). Available from: http://cost.jsc.nasa.gov/ inflateGDP.html
16. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. Am J Respir Crit Care Med 2000;162:460-464. (Pubitemid 30647184)
17. Gourevitch MN, Alcabes P, Wasserman WC, Arno PS. Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. Int J Tuberc Lung Dis 1998;2:531-540. (Pubitemid 28320059)
18. Perlman DC, Gourevitch MN, Trinh C, Salomon N, Horn L, Des J. Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program. J Urban Health 2001;78:550-567. (Pubitemid 32852792)
19. Aspler A, Dion MJ, Long R, Trajman A, Yang J, Al Jahdali H, Khan K, Gardam M, Wobeser W, Hoeppner V, et al. Costs and cost-effectiveness of a randomized trial of 4 months rifampin versus 9 months of isoniazid for treatment of latent tuberculosis infection (LTBI) [abstract]. Am J Respir Crit Care Med 2008;177:A790.
20. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2006. (Accessed September 9, 2007.) Available from: http://www.cdc.gov/nchstp/tb/surv/surv2006/default.htm.
21. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Desaef A, Verpooten GA, Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-818.
22. Brown RE, Miller B, Taylor WR, Palmer C, Bosco L, Nicola RM, Zelinger J, Simpson K. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995;155:1595-1600.
23. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, Miller B. Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 2000;4:931-939.
24. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Bae S, Drewyer G, Weis SE. Using the St. George respiratory questionnaire to ascertain health quality in persons with treated pulmonary tuberculosis. Chest 2007;132:1591-1598.
25. Miller TL. A cost analysis of tuberculosis and its prevention in Tarrant County, Texas [MS thesis]. University of North Texas, 2007.
26. Kohn MR, Arden MR, Vasilakis J, Shenker IR. Directly observed preventive therapy: turning the tide against tuberculosis. Arch Pediatr Adolesc Med 1996;150:727-729. (Pubitemid 26230873)
27. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018. (Pubitemid 29143893)
28. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, Peloquin CA, Gordin FM, Nunes D, Strader DB, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-952. (Pubitemid 44564795)
29. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/ British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
30. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jaldali H, Memish Z, Khan K, Gardam M, Hoeppner V, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149: 689-697.
31. Page KR, Sifakis F, de Montes OR, Cronin WA, Doherty MC, Federline L, Bur S, Walsh T, Karney W, Milman J, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006;166:1863-1870. (Pubitemid 44455169)
32. State of North Carolina Tuberculosis Control Program. 2007 tuberculosis statistics for North Carolina. (Accessed December 19, 2008.) Available from: http://www.epi.state.nc.us/epi/tb/pdf/tbannual2007.pdf.
33. Salpeter EE, Salpeter SR. Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection- delay function. Am J Epidemiol 1998;147:398-406. (Pubitemid 28106895)
34. Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, FitzGerald JM. Health state utilities in latent and active tuberculosis. Value Health 2008;11:1154-1161.
35. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997; 127:1051-1061. (Pubitemid 28012074)
36. Burman WJ, Dalton CB, Cohn DL, Butler JR, Reves RR. A cost-effectiveness analysis of directly observed therapy vs self-administered therapy for treatment of tuberculosis. Chest 1997;112:63-70. (Pubitemid 27343601)
37. Snyder DC, Chin DP. Cost-effectiveness analysis of directly observed therapy for patients with tuberculosis at low risk for treatment default. Am J Respir Crit Care Med 1999;160:582-586. (Pubitemid 29380676)